Aegle Therapeutics Company

Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare genetic pediatric connective tissue disorder.
Technology: Other
Industry: Stem Cell Exhaustion
Headquarters: United States
Investors Number: 25
Total Funding: $175.2M
Estimated Revenue: $1M to $10M
Last Funding Type: Debt Financing

Visit Website
Register and Claim Ownership